All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Bookmark this article
During the 20th International Myeloma Society Annual Meeting 2023, the Multiple Myeloma Hub was pleased to speak to Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR. We asked, What are the pros and cons of bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapies in myeloma?
What are the pros and cons of bispecific antibodies and CAR T-cell therapies in myeloma?
In this video interview, Mohamad Mohty opens by discussing the latest developments and approvals for CAR T-cell and bispecific antibody therapies for the treatment of relapsed/refractory multiple myeloma. Mohty goes on to discuss the considerations for the use of each type of agent, including manufacturing times, commercial availability, and the associated adverse events. This interview concludes with a look towards the future myeloma treatment landscape, and how these treatments may be sequenced and combined, and the impact this may have on patient outcomes.
EHA2023 abstracts: What's hot in multiple myeloma and other plasma cell dyscrasias?
To help navigate the exciting content being presented at the EHA2023 Congress, the Multiple Myeloma Hub Steering Committee have provided their recommendations for the...
Access and future prospects of advanced immunotherapies for multiple myeloma in Europe
During the 4th European CAR T-cell Meeting, the Multiple Myeloma Hub was pleased to speak with Michel Delforge, UZ Leuven, Leuven, BE. We asked, What are the...
Subscribe to get the best content related to multiple myeloma delivered to your inbox